Patents by Inventor Federica Pericle

Federica Pericle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS RELATED TO XCT ANTIBODIES
    Publication number: 20220213187
    Abstract: Certain embodiments are directed to therapeutic compositions having an xCT specific antibody.
    Type: Application
    Filed: May 8, 2020
    Publication date: July 7, 2022
    Inventors: FEDERICA CAVALLO, AHMAD SALAMEH, JERRI CALDEIRA, FEDERICA PERICLE
  • Compositions and methods related to xCT antibodies
    Patent number: 11059901
    Abstract: Certain embodiments are directed to therapeutic compositions having an xCT specific antibody.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: July 13, 2021
    Assignee: Agilvax Inc.
    Inventors: Federica Pericle, John O′Rourke, Federica Cavallo
  • Compositions and methods related to xCT peptides
    Patent number: 11040223
    Abstract: Certain embodiments are directed to composition for inducing an immune response against xCT that is directed to cancer stem cells expressing xCT.
    Type: Grant
    Filed: March 16, 2020
    Date of Patent: June 22, 2021
    Assignee: Agilvax Inc.
    Inventors: Federica Cavallo, Stefania Lanzardo, Laura Conti, John P. O'Rourke, Federica Pericle
  • COMPOSITIONS AND METHODS RELATED TO xCT PEPTIDES
    Publication number: 20200316147
    Abstract: Certain embodiments are directed to composition for inducing an immune response against xCT that is directed to cancer stem cells expressing xCT.
    Type: Application
    Filed: March 16, 2020
    Publication date: October 8, 2020
    Inventors: Federica CAVALLO, Stefania LANZARDO, Laura CONTI, John P. O'ROURKE, Federica PERICLE
  • COMPOSITIONS AND METHODS RELATED TO xCT ANTIBODIES
    Publication number: 20200148784
    Abstract: Certain embodiments are directed to therapeutic compositions having an xCT specific antibody.
    Type: Application
    Filed: April 30, 2018
    Publication date: May 14, 2020
    Inventors: Federica PERICLE, John O'ROURKE, Federica CAVALLO
  • Compositions and methods related to xCT peptides
    Patent number: 10588953
    Abstract: Certain embodiments are directed to composition for inducing an immune response against xCT that is directed to cancer stem cells expressing xCT.
    Type: Grant
    Filed: December 18, 2016
    Date of Patent: March 17, 2020
    Assignee: AGILVAX, INC.
    Inventors: Federica Cavallo, Stefania Lanzardo, Laura Conti, John P. O'Rourke, Federica Pericle
  • COMPOSITIONS AND METHODS RELATED TO xCT PEPTIDES
    Publication number: 20180360935
    Abstract: Certain embodiments are directed to composition for inducing an immune response against xCT that is directed to cancer stem cells expressing xCT.
    Type: Application
    Filed: December 18, 2016
    Publication date: December 20, 2018
    Inventors: Federica CAVALLO, Stefania LANZARDO, Laura CONTI, John P. O'ROURKE, Federica PERICLE
  • Compositions and methods related to inhibitors of JAK kinase
    Patent number: 9371265
    Abstract: Embodiments are directed to JAK kinase inhibiting prodrug compounds of Formula Ib, containing a promoiety that results in alcohol derivative of the parent compound upon removal and methods of using an effective amount of said prodrug compounds in the treatment of a JAK-mediated disease or disorder in a subject. Preferred promoieties include phosphate, phosphonate, phosphate salt, sulfate, or sulfate salt.
    Type: Grant
    Filed: March 26, 2013
    Date of Patent: June 21, 2016
    Inventors: Federica Pericle, Jeremy A. Ross
  • COMPOSITIONS AND METHODS RELATED TO INHIBITORS OF JAK KINASE
    Publication number: 20150087621
    Abstract: Embodiments are directed to JAK kinase inhibiting prodrug compounds of Formula Ib, containing a promoiety that results in alcohol derivative of the parent compound upon removal and methods of using an effective amount of said prodrug compounds in the treatment of a JAK-mediated disease or disorder in a subject. Preferred promoieties include phosphate, phosphonate, phosphate salt, sulfate, or sulfate salt.
    Type: Application
    Filed: March 26, 2013
    Publication date: March 26, 2015
    Inventors: Federica Pericle, Jeremy A. Ross
  • LACTOFERRIN IN THE TREATMENT OF MALIGNANT NEOPLASMS AND OTHER HYPERPROLIFERATIVE DISEASES
    Publication number: 20120276126
    Abstract: The present invention relates to methods of treating a hyperproliferative disease by administering a composition of lactoferrin alone or in combination with standard anti-cancer therapies.
    Type: Application
    Filed: July 11, 2012
    Publication date: November 1, 2012
    Applicant: AGENNIX AG
    Inventors: Atul Varadhachary, Rick Barsky, Federica Pericle, Karel Petrak, Yenyun Wang
  • Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
    Patent number: 8242079
    Abstract: The present invention relates to methods of treating a hyperproliferative disease by administering a composition of lactoferrin alone or in combination with standard anti-cancer therapies.
    Type: Grant
    Filed: December 9, 2010
    Date of Patent: August 14, 2012
    Assignee: Agennix Incorporated
    Inventors: Atul Varadhachary, Rick Barsky, Federica Pericle, Karel Petrak, Yenyun Wang
  • Lactoferrin as an adjuvant in cancer vaccines
    Patent number: 8105615
    Abstract: The present invention relates to methods of treating cancer by administering a composition of lactoferrin (LF) in combination with cancer vaccines.
    Type: Grant
    Filed: June 7, 2004
    Date of Patent: January 31, 2012
    Assignee: Agennix Incorporated
    Inventors: Atul Varadhachary, Federica Pericle
  • Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
    Patent number: 8058234
    Abstract: The present invention relates to methods of using lactoferrin (LF) to treat, prevent or reduce the incidence of organ transplant rejection and graft-versus-host-disease. More particularly, the present invention relates to methods of reducing an immune response against miss-matched transplanted organs such as kidney, heart, lung, liver, pancreas and stem cells by administering a composition of lactoferrin to the recipient patients. In addition, this invention relates to the treatment of bone marrow transplant (BMT) donors with lactoferrin to attenuate the development of graft-versus-host-disease in the recipients. Moreover, this invention relates to the treatment of xenograft organ donors with lactoferrin to attenuate the development of graft rejection in the recipients.
    Type: Grant
    Filed: August 17, 2009
    Date of Patent: November 15, 2011
    Assignee: Agennix Incorporated
    Inventors: Atul Varadhachary, Federica Pericle
  • LACTOFERRIN AS AN ADJUVANT IN CANCER VACCINES
    Publication number: 20110110983
    Abstract: The present invention relates to methods of treating cancer by administering a composition of lactoferrin (LF) in combination with cancer vaccines.
    Type: Application
    Filed: September 8, 2009
    Publication date: May 12, 2011
    Inventors: Atul Varadhachary, Federica Pericle
  • LACTOFERRIN IN THE TREATMENT OF MALIGNANT NEOPLASMS AND OTHER HYPERPROLIFERATIVE DISEASES
    Publication number: 20110076295
    Abstract: The present invention relates to methods of treating a hyperproliferative disease by administering a composition of lactoferrin alone or in combination with standard anti-cancer therapies.
    Type: Application
    Filed: December 9, 2010
    Publication date: March 31, 2011
    Inventors: Atul Varadhachary, Rick Barsky, Federica Pericle, Karel Petrak, Yenyun Wang
  • Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
    Patent number: 7901879
    Abstract: The present invention relates to methods of treating a hyperproliferative disease by administering a composition of lactoferrin alone or in combination with standard anti-cancer therapies.
    Type: Grant
    Filed: May 9, 2003
    Date of Patent: March 8, 2011
    Assignee: Agennix Incorporated
    Inventors: Atul Varadhachary, Rick Barsky, Federica Pericle, Karel Petrak, Yenyun Wang
  • Dosing Regimen for the Treatment of Alzheimer's Disease With Sulfonyl Fluorides
    Publication number: 20100256243
    Abstract: The present invention provides for improved dosing regimens for the provision of sulfonyl fluorides, such a methanesulfonyl fluoride (MSF) to subjects suffering from Alzheimer's Disease (AD). The methods rely on an alternating day dosing scheme that avoids toxicity associated with a daily dosing regimen.
    Type: Application
    Filed: April 3, 2009
    Publication date: October 7, 2010
    Inventors: Federica Pericle, Enrico Braglia
  • LACTOFERRIN AS AN AGENT IN THE PREVENTION OF ORGAN TRANSPLANT REJECTION AND GRAFT-VERSUS-HOST-DISEASE
    Publication number: 20090318334
    Abstract: The present invention relates to methods of using lactoferrin (LF) to treat, prevent or reduce the incidence of organ transplant rejection and graft-versus-host-disease. More particularly, the present invention relates to methods of reducing an immune response against miss-matched transplanted organs such as kidney, heart, lung, liver, pancreas and stem cells by administering a composition of lactoferrin to the recipient patients. In addition, this invention relates to the treatment of bone marrow transplant (BMT) donors with lactoferrin to attenuate the development of graft-versus-host-disease in the recipients. Moreover, this invention relates to the treatment of xenograft organ donors with lactoferrin to attenuate the development of graft rejection in the recipients.
    Type: Application
    Filed: August 17, 2009
    Publication date: December 24, 2009
    Inventors: Atul Varadhachary, Federica Pericle
  • Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
    Patent number: 7592306
    Abstract: The present invention relates to methods of using lactoferrin (LF) to treat, prevent or reduce the incidence of organ transplant rejection and graft-versus-host-disease. More particularly, the present invention relates to methods of reducing an immune response against miss-matched transplanted organs such as kidney, heart, lung, liver, pancreas and stem cells by administering a composition of lactoferrin to the recipient patients. In addition, this invention relates to the treatment of bone marrow transplant (BMT) donors with lactoferrin to attenuate the development of graft-versus-host-disease in the recipients. Moreover, this invention relates to the treatment of xenograft organ donors with lactoferrin to attenuate the development of graft rejection in the recipients.
    Type: Grant
    Filed: December 10, 2003
    Date of Patent: September 22, 2009
    Assignee: Agennix, Inc.
    Inventors: Atul Varadhachary, Federica Pericle
  • Lactoferrin as an adjuvant in cancer vaccines
    Publication number: 20050019342
    Abstract: The present invention relates to methods of treating cancer by administering a composition of lactoferrin (LF) in combination with cancer vaccines.
    Type: Application
    Filed: June 7, 2004
    Publication date: January 27, 2005
    Inventors: Atul Varadhachary, Federica Pericle